COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
Vitamin D study #37 of 50
11/17 Late treatment study
Murai et al., medRxiv, doi:10.1101/2020.11.16.20232397 (Preprint)
Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19: A Multicenter, Double-blind, Randomized Controlled Trial
Source   PDF   Share   Tweet
Very late stage (mean 10 days from symptom onset, 90% on oxygen at baseline) vitamin D supplementation RCT not showing significant differences.
Ethnicity was poorly matched between arms, and diabetes was 41% in the treatment arm vs. 29% in the control arm. Baseline ventilation was 15% in the treatment arm vs. 12% control, this alone may account for the higher mortality. Calcifediol, which avoids several days delay in conversion, may be more successful, especially with this very late stage usage.

Murai et al., 11/17/2020, Randomized Controlled Trial, Brazil, South America, preprint, 17 authors, dosage 200,000IU single dose.
risk of death, 38.0% higher, RR 1.38, p = 0.59, treatment 8 of 114 (7.0%), control 6 of 118 (5.1%).
risk of ventilation, 51.3% lower, RR 0.49, p = 0.09, treatment 8 of 114 (7.0%), control 17 of 118 (14.4%).
risk of ICU admission, 25.5% lower, RR 0.75, p = 0.31, treatment 18 of 114 (15.8%), control 25 of 118 (21.2%).
Details of all 50 studies
Please submit corrections, updates, or comments.
Submit